Thomas Ybert

USPTO Granted Patents = 16 (Patent Applications = 10)

CIPO Patents = 3 (Patent Applications = 9)

EPO Patents = 6 (Patent Applications = 18)

Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 29(Granted Patents)

Company Filing History:

Centre National De La Recherche Scientifique

patents

5. 1 out of 1

National Center for Scientific Research (cnrs)

patent

6. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421628 - Massively parallel enzymatic synthesis of nucleic acid strands (2025-09-23),

2. 12377397 - Systems, apparatus and kits for enzymatic polynucleotide synthesis (2025-08-05),

3. 12286652 - Variants of terminal deoxynucleotidyl transferase and uses thereof (2025-04-29),

4. 12173333 - Variants of family a DNA polymerase and uses thereof (2024-12-24),

5. 12071638 - Variants of terminal deoxynucleotidyl transferase and uses thereof (2024-08-27),

6. 11993773 - Methods for extending polynucleotides (2024-05-28),

7. 11685941 - Method for synthesizing nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method (2023-06-27),

8. 11661436 - Method for preparing 3'-o-amino-2′-deoxyribonucleoside-5′-triphosphates (2023-05-30),

9. 11390856 - Variants of family a DNA polymerase and uses thereof (2022-07-19),

10. 11268091 - Direct oligonucleotide synthesis on cells and biomolecules (2022-03-08),

11. 11208637 - Variants of terminal deoxynucleotidyl transferase and uses thereof (2021-12-28),

12. 11059849 - Modified nucleotides for synthesis of nucleic acids, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes (2021-07-13),

13. 10913964 - Method for synthesizing nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method (2021-02-09),

14. 10837040 - Method for synthesizing nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method (2020-11-17),

15. 10752887 - Variants of terminal deoxynucleotidyl transferase and uses thereof (2020-08-25),

Title: The Innovative Contributions of Thomas Ybert

Introduction

Thomas Ybert is a prominent inventor based in Paris, France, known for his significant contributions to the field of enzymatic synthesis of nucleic acids. With a total of 16 patents to his name, Ybert has made remarkable advancements that have the potential to revolutionize genetic research and biotechnology.

Latest Patents

One of Ybert's latest patents is focused on the massively parallel enzymatic synthesis of nucleic acid strands. This invention outlines methods for template-free enzymatic synthesis of various polynucleotides with predetermined sequences. The methods utilize large-scale arrays of reaction sites, each linked to at least one working electrode, to control deprotection and deblocking steps at user-selected sites. Another notable patent involves systems, apparatus, and kits for automated synthesis of multiple polynucleotides in an array of reaction chambers using a template-free polymerase. This invention includes adaptive elements to monitor and control the synthesis process and fluid movement, addressing challenges such as enzyme aggregation.

Career Highlights

Throughout his career, Thomas Ybert has worked with esteemed organizations such as Dna Script and Institut Pasteur. His work in these institutions has allowed him to push the boundaries of current technologies in nucleic acid synthesis.

Collaborations

Ybert has collaborated with notable colleagues, including Elise Champion and Sylvain Gariel, contributing to a dynamic environment of innovation and research.

Conclusion

Thomas Ybert's innovative work in enzymatic synthesis has positioned him as a key figure in biotechnology. His patents reflect a commitment to advancing the field and improving methodologies for nucleic acid synthesis.

This text is generated by artificial intelligence and may not be accurate.